The mother notices it first — a patch of dry, angry-red skin behind her baby's knees, weeping and crusting. The child scratches constantly at night, waking the whole household. By morning, the scratched skin is raw. This is atopic dermatitis (AD) — the most common chronic inflammatory skin disease in the world, and an increasingly frequent visitor in Indian homes, particularly in cities where air quality is poor, water is hard, and modern detergents and synthetic fabrics are everywhere.
In India, AD affects an estimated 4–10% of children and is rising — driven by urbanisation, pollution, changes in the skin microbiome, and the "hygiene hypothesis." While psoriasis tends to dominate dermatology conversations, atopic dermatitis is actually more common, starts earlier in life, and carries a significant psychological burden — for both the child and their family. If your child has persistent itchy skin that worsens at night, or if you yourself have a recurrent, itchy rash in the skin folds — this guide is for you.
What Is Atopic Dermatitis? (It Is More Than "Just Eczema")
Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterised by intense itching (pruritus), dry skin (xerosis), and a characteristic rash distribution that changes with age. It is the skin component of atopy — an inherited tendency to develop allergic diseases — which also includes asthma and allergic rhinitis (hay fever). The three often travel together in Indian families: if a child has AD, they have a 30–50% chance of developing asthma, and vice versa.
The term "eczema" is often used interchangeably with atopic dermatitis, though technically eczema is a broader term for various types of skin inflammation. When Indians say "eczema" in a clinical setting, they nearly always mean atopic dermatitis.
The Core Problem: A Defective Skin Barrier
In AD, mutations in the gene encoding filaggrin (a protein essential for maintaining the skin's barrier function) allow allergens, irritants, and microbes to penetrate the skin, triggering an immune response. This explains why:
- AD skin is abnormally dry — it cannot retain moisture
- The skin overreacts to normally harmless substances (dust mites, pet dander, sweat, synthetic fabric)
- Staphylococcus aureus colonises AD skin and worsens inflammation
- Moisturising is not optional — it is the foundation of treatment
How Common Is Atopic Dermatitis in India?
The exact burden is harder to pin down than in Western populations due to limited nationwide data, but what we know:
- Prevalence in Indian children: Studies report 4–10% in urban Indian children, rising steadily over the past two decades. Urban prevalence (76.9% of cases) significantly exceeds rural (23.1%)
- Global comparison: India's prevalence is lower than Western countries (where it reaches 15–25% of children), but the absolute numbers are enormous — India's population means tens of millions of affected children
- Geographic variation: Higher rates in North India and urban centres; lower in rural South India. The ISAAC (International Study of Asthma and Allergies in Childhood) study found lower rates in Jodhpur but Indian urban hospital-based studies consistently show AD as a top dermatology complaint
- Adults are also affected: While AD peaks in infancy and childhood, approximately 10–30% of cases persist into adulthood. In India, adult-onset AD also occurs, especially in individuals with occupational exposures
- The IADVL STAND-AD Consensus (2023): The Indian Association of Dermatologists, Venereologists and Leprologists Special Interest Group issued dedicated Indian guidelines (STAND-AD) for the first time, recognising that Indian patients have distinct features
Why India Has Specific Drivers of Atopic Dermatitis
Several factors make AD more challenging in the Indian context:
1. Hard Water and Water Quality
Studies across India show that hard water (high calcium and magnesium content) is associated with higher rates of childhood eczema. Indian groundwater in many cities — Delhi, Bengaluru, Hyderabad, Pune — has high hardness. Hard water raises skin pH, compromises the skin barrier, and makes soap residue more irritating.
2. Air Pollution and PM2.5
India's air quality crisis is a genuine contributor to AD. Particulate matter (PM2.5), diesel exhaust particles, and nitrogen dioxide from traffic pollution activate skin immune pathways and worsen the skin barrier. Children growing up near busy Indian roads or in high-pollution cities have measurably higher rates of AD.
3. Dietary Factors and Food Allergy
Indian food culture is rich and diverse, but AD children in India are frequently sensitised to:
- Cow's milk — the most common trigger in infants; India's formula market and early cow's milk introduction are relevant
- Eggs — a common trigger in toddlers
- Wheat — especially in North Indian diets heavy in maida
- Peanuts (groundnuts) — widely consumed in Indian snacks
- Fish — especially in coastal regions
However, food allergy testing in AD is frequently overused. The IADVL guidelines caution that positive food allergy tests (RAST or skin prick tests) in AD do not always mean the food is causing flares — clinical correlation is essential before eliminating a food, especially given India's nutritional deficiency burden.
4. Clothing and Fabric
India's heat and humidity mean children spend much of the year sweating, and sweat is a potent AD trigger. Synthetic fabrics trap heat; tight elastic waistbands cause localised eczema. Cotton and soft, loose-fitting clothing is essential.
5. Cultural Practices
- Bathing practices: Vigorous scrubbing with rough towels or loofahs, harsh soaps, or prolonged hot water baths all damage the skin barrier. Indian families often bathe children with rough-textured towels, which exacerbates AD
- Mehendi (henna): Black henna (with para-phenylenediamine/PPD) is a potent sensitiser and should be strictly avoided in AD children
- Kumkum and sindhoor: Contain dyes that can trigger contact dermatitis on top of AD in some patients
- Coconut oil vs. emollients: Many Indian families use coconut oil as a moisturiser. Studies show coconut oil actually impairs skin barrier function and increases Staphylococcus aureus colonisation in AD — sunflower oil is a better choice for Indian patients without a nut allergy
Recognising Atopic Dermatitis: Age-Based Pattern
AD has a characteristic distribution pattern that changes with age:
Infantile AD (0–2 years)
- Face and scalp: Red, weeping, crusting patches on cheeks and forehead; relative sparing of the nose and diaper area
- Extensor surfaces: Shins, forearms
- Intense itch; infant scratches and rubs face on bedding
- Sleep disturbance is severe — a major family quality-of-life issue
Childhood AD (2–12 years)
- Flexural creases: Inside the elbows, behind the knees — the classic "antecubital and popliteal fossae" distribution
- Neck and wrists
- Chronic lichenification (thickened, leathery skin from repeated scratching) — very common in Indian children who have had untreated AD for years
- Secondary infection: honey-coloured crusting (impetigo) from S. aureus or viral infection (eczema herpeticum — a medical emergency)
Adolescent and Adult AD
- Flexures remain involved
- Hands and fingers (hand eczema) — very common in adults, triggered by frequent hand-washing, detergent exposure
- Around eyes and mouth
- Nummular (coin-shaped) patches
- Nipple eczema in young women
Atopic Dermatitis vs. Other Skin Conditions
| Feature | Atopic Dermatitis | Psoriasis | Contact Dermatitis | Seborrhoeic Dermatitis |
|---|---|---|---|---|
| Age of onset | Infancy/childhood | Any age | Any age | Infancy or adults |
| Location | Flexures, face | Extensor surfaces, scalp | Site of contact | Scalp, face, chest |
| Itch | Intense (primary feature) | Mild to moderate | Moderate to severe | Mild |
| Skin appearance | Dry, weeping, lichenified | Thick, silvery plaques | Blistering, swollen | Greasy, yellowish scales |
| Family history | Atopy (asthma, hay fever) | Psoriasis | No | No |
Diagnosing Atopic Dermatitis in India
AD is diagnosed clinically — there is no specific blood test. The Hanifin and Rajka criteria are widely used: diagnosis requires at least 3 major and 3 minor features.
Major criteria: Pruritus, typical morphology and distribution, chronic or chronically-relapsing history, personal or family history of atopy
Minor criteria (selected examples): Early age of onset, xerosis, elevated serum IgE, food hypersensitivity, perifollicular accentuation (especially in darker Indian skin), Dennie-Morgan infraorbital folds (extra skin fold under the eye — very common in Indian AD)
Blood Tests and Investigations
| Test | Purpose | Typical Finding in AD |
|---|---|---|
| Total serum IgE | Confirms atopic tendency | Elevated (often >200 IU/mL, sometimes >1000 IU/mL) |
| CBC with differential | Look for eosinophilia | Often elevated eosinophils |
| Specific IgE (RAST) | Identify specific allergens (dust mites, food, pet dander) | Positive to relevant allergens |
| Skin Prick Test (SPT) | Allergen testing | Positive wheals to triggers |
| Patch testing | Identify contact allergen if contact dermatitis suspected | Identifies specific sensitisers |
| Swab culture (C&S) | Diagnose secondary bacterial infection | S. aureus growth in infected areas |
| Tzanck smear / HSV PCR | Rule out eczema herpeticum | If vesicular lesions appear suddenly |
Cost in India: Total IgE costs approximately ₹500–₹800 at labs like SRL, Dr. Lal PathLabs, or Thyrocare. Specific IgE panels run ₹2,000–₹6,000 depending on the number of allergens tested.
SCORAD and IGA — How Doctors Measure Severity
Dermatologists use objective scoring tools:
- IGA (Investigator's Global Assessment): Scale of 0–4; used to assess treatment response in clinical practice and trials
- SCORAD (SCORing Atopic Dermatitis): 0–103 scale; takes into account area affected, intensity, and patient symptoms. Mild: < 25, Moderate: 25–50, Severe: > 50
Treatment of Atopic Dermatitis: The Step-Up Approach
Foundation: Emollients (Moisturisers)
The cornerstone of ALL AD management, regardless of severity. Emollients restore the skin barrier, reduce water loss, and directly reduce the need for topical corticosteroids.
How to use emollients in India:
- Apply within 3 minutes of bathing, while skin is still slightly damp ("soak and smear")
- Use a thick cream or ointment, not a lotion — ointments are most occlusive but can cause folliculitis in India's hot weather; thick creams (like CeraVe, Sebamed, Cetaphil) are practical alternatives
- Apply liberally at least twice daily; the "fingertip unit" rule: 1 FTU (the amount squeezed from fingertip to first crease) covers an area equal to 2 adult palms
- Indian-available emollient brands: Atoderm (Bioderma), Lipikar (La Roche-Posay), Cetaphil Moisturising Cream, Sebamed Baby Cream, Vaseline Intensive Care for mild cases
⚠️ Avoid petroleum jelly (Vaseline) alone on open, infected skin, and avoid coconut oil in AD despite its cultural popularity.
Step 1: Mild AD — Topical Corticosteroids (TCS)
Topical corticosteroids remain the first-line treatment for AD flares across all guidelines, including IADVL STAND-AD.
Potency guide for India:
| Potency | Drug | Indian Brand | Use |
|---|---|---|---|
| Mild | Hydrocortisone 1% | Cortiphos, Hycort | Face, eyelids, skin folds |
| Moderate | Betamethasone valerate 0.025-0.1% | Betnovate, Betnesol | Body, short courses on face |
| High | Mometasone furoate 0.1% | Elomet, Momate | Thickened lichenified patches on body |
| Very High | Clobetasol propionate 0.05% | Tenovate, Dermovate | Severe lichenified areas only, very short courses |
The "fingertip unit" rule applies: Use sparingly but sufficiently. Under-treatment is common in India due to steroid phobia — parents often apply TCS too little, too briefly, and then suffer rebound flares.
Step 2: Moderate AD — Topical Calcineurin Inhibitors (TCIs)
When steroids are inappropriate (face, eyelids, skin folds) or when steroid-sparing is needed, tacrolimus (Protopic — 0.03% for children, 0.1% for adults) and pimecrolimus (Elidel) are used.
These are non-steroidal and do not cause skin thinning. They are now approved and available in India, though cost is higher (Protopic 0.03% ointment: approximately ₹400–₹700 for 10g). They cause an initial burning sensation for the first few days — warn patients.
Proactive therapy: In moderate-severe AD, applying TCS or TCI 2 days per week to previously affected areas (even when clear) dramatically reduces flares — an evidence-based strategy underused in India.
Step 3: Moderate-Severe AD — Systemic Treatments
Antihistamines: Widely used in India (cetirizine, loratadine, hydroxyzine) for sleep disruption and itch relief. Non-sedating antihistamines have limited evidence for AD itch (which is not histamine-mediated); sedating hydroxyzine (Atarax) is useful at night to break the scratch-sleep cycle.
Systemic immunosuppressants (for severe, recalcitrant AD):
- Cyclosporine (Neoral, Panimun): Fast-acting; requires blood pressure and kidney function monitoring; available in India (₹2,000–₹5,000/month)
- Methotrexate: Weekly low-dose; requires LFT monitoring; cost-effective in India (₹100–₹300/month); slow onset (8–12 weeks)
- Azathioprine: Another option; requires TPMT enzyme testing before use; cost-effective
Phototherapy (NB-UVB):
- Narrowband UVB phototherapy — 3 sessions per week for 12–16 weeks — is highly effective and available at major dermatology centres and medical college hospitals in India
- Cost: ₹200–₹500 per session at government hospitals; ₹500–₹1,500 at private centres
Step 4: Severe AD — Biologic Therapy
Dupilumab (Dupixent) — a monoclonal antibody targeting IL-4 and IL-13 signalling — is the first biologic approved for moderate-to-severe AD and has transformed outcomes for patients who fail conventional therapy.
- Available in India: Yes, since 2022 (Sanofi)
- Dose: 600mg SC loading dose, then 300mg every 2 weeks (adults)
- Approved age: 6 months and above (adult and paediatric indications)
- Efficacy: 50–70% of patients achieve clear or almost clear skin (IGA 0/1) at 16 weeks
- Cost in India: ₹40,000–₹70,000 per injection — a major barrier; advocacy for inclusion in PM-JAY and state schemes is ongoing
- Side effects: Conjunctivitis (common — use eye drops); injection site reactions; very safe compared to immunosuppressants
Tralokinumab (another IL-13 inhibitor) and lebrikizumab are also being evaluated in India.
JAK inhibitors (topical and oral):
- Ruxolitinib cream (Opzelura) — topical JAK1/2 inhibitor; approved in USA for mild-moderate AD; not yet widely available in India
- Upadacitinib (Rinvoq) and abrocitinib (Cibinqo) — oral JAK inhibitors; available at major tertiary centres in India; cost remains very high (₹60,000–₹1.5 lakh/month)
Practical Tips for Managing AD in the Indian Home
The Indian Bathing Protocol for AD
- Use lukewarm water (not hot) — hot water destroys skin lipids
- Limit bath to 5–10 minutes
- Use a gentle, soap-free cleanser: Sebamed Baby Wash, Cetaphil Gentle Cleansing Bar, Bioderma Atoderm Gel
- Pat dry gently with a soft cotton towel — never rub
- Apply emollient within 3 minutes of towel-drying
Managing the Indian Summer and Monsoon
- Summer: Sweat is a major trigger — use lightweight cotton clothing, keep AC at 24–26°C, apply emollient after sweating
- Monsoon: Humidity increases S. aureus and fungal colonisation; keep skin folds dry; bath twice daily during high humidity periods
- Winter: Dry, cold weather worsens xerosis — increase emollient frequency; use a room humidifier at night
Dust Mite Reduction (the Most Important Allergen in Indian Homes)
House dust mites (Dermatophagoides pteronyssinus) are the most common indoor aeroallergen in Indian AD:
- Wash bedding in hot water (≥60°C) weekly
- Use allergen-impermeable pillow and mattress covers (available on Flipkart/Amazon: approx ₹500–₹1,500)
- Avoid carpets and heavy curtains in the child's bedroom
- Vacuum mattresses and furniture regularly
- Reduce soft toys on the bed; wash them regularly in hot water
Identifying and Managing Flares
A flare diary is invaluable — note down what changed 24–48 hours before a flare: new food, a new soap or shampoo, a visit to a dusty environment, stress, illness. Apps and digital health records (such as MedicalVault's) can help you track patterns across doctor visits and identify your child's specific triggers.
If a flare starts:
- Increase emollient frequency immediately
- Start TCS as prescribed by your doctor — do not wait
- Look for signs of infection (honey-coloured crusting, fever, rapidly worsening pain): if present, see your doctor — antibiotics or antivirals may be needed
- Cool the skin: a cool (not cold) wet compress for 10–15 minutes relieves acute itch
The Emotional Burden — For the Child and the Family
AD is not just a skin disease. Multiple Indian studies have documented:
- Sleep deprivation in >70% of affected children and their caregivers
- School absenteeism and academic difficulty from chronic itch and sleep disruption
- Anxiety and depression in school-age children with visible skin disease
- Parental distress and guilt — common when itching persists despite treatment
Validate these struggles. Indian families often suffer in silence, trying home remedies or rotating through doctors without a clear management plan. A structured written plan from your dermatologist — covering daily emollient use, what TCS to apply and when, when to escalate — dramatically improves outcomes. Consider keeping this plan digitally using MedicalVault's records storage feature so it's accessible to all family caregivers.
Tracking Your Child's AD Over Time
Monitor the following at every dermatology visit:
- SCORAD or IGA score (ask your dermatologist to document it)
- Flare frequency (number of significant flares per month)
- Sleep quality (nights per week disrupted by itch)
- School/activity participation
- Total IgE and eosinophil count on blood tests — rising IgE often correlates with worsening atopic march
Use MedicalVault's family health records to keep blood test results, dermatology reports, and treatment plans together — especially useful for families managing a child's condition across multiple healthcare providers (general paediatrician, allergist, dermatologist).
Key Takeaways
- Atopic dermatitis affects 4–10% of Indian children and is rising in urban areas, driven by pollution, hard water, and changing lifestyles
- It is a systemic atopic disease — affected children have elevated risk of asthma and allergic rhinitis ("the atopic march")
- The Indian skin-care cultural default — coconut oil, vigorous scrubbing, harsh soaps — actively harms the AD skin barrier; switch to gentle cleansers + medically appropriate emollients
- Moisturising twice daily, every day is the single most important treatment — underused in India
- Topical corticosteroids remain first-line for flares and are safe when used correctly; steroid phobia leads to under-treatment and chronicity
- Dupilumab is now available in India and is transformative for severe AD — though cost remains a barrier
- Track flare triggers, test results, and treatment plans using MedicalVault's digital health records platform to ensure continuity of care and better outcomes for your child